On November 8, 2023 Corner Therapeutics, a biotechnology company exploiting a new scientific paradigm to boost the immune response to disease, reported the first publication detailing their proprietary Catalytic Adjuvant platform that drives strong T cell immune responses to mRNA vaccines (Press release, Corner Therapeutics, NOV 8, 2023, View Source [SID1234637299]). The publication in the journal mBio is titled "mRNAs encoding self-DNA reactive cGAS enhance the immunogenicity of lipid nanoparticle vaccines".

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lipid nanoparticles (LNPs) have been used to stimulate immunity to mRNA-encoded antigenic proteins from viruses and cancers. However, immune durability is limiting with current LNP vaccines, as the strategies used do not activate T cells robustly, which are key for immune memory. The lack of immune memory from current LNP-mRNA vaccination approaches is linked to a decades-old observation in medical science — antigens are not sufficient to stimulate durable immunity. Durable immunity is only activated when antigens are combined with molecules that mimic an infection. These infection mimics, known as adjuvants, are commonly found in other vaccines, but not current formulations of LNP-mRNA vaccines. This publication describes Corner’s discovery of a new class of immunostimulatory enzymes known as catalytic adjuvants, encoded by mRNAs in LNPs. The mRNA encoded catalytic adjuvant is a variant of the innate immune receptor cGAS, which activates the highly immunostimulatory STING pathway in dendritic cells (DCs), which control durable T cell immunity to cancer and infection. Corner’s catalytic adjuvants induce numerous DC activities that are needed for durable immunity, including the upregulation of chemokine receptors, T cell costimulatory molecules, major histocompatibility complex proteins, cytokines, and type I interferons. This discovery reveals that mRNA-encoded proteins can provide more than antigenic signals to the immune system. Proteins with adjuvant activities can also be encoded on mRNAs, leading to robust immune cell activation.

When co-administered with LNP vaccines encoding antigens, akin to those used clinically, catalytic adjuvants stimulated durable antigen-specific T cell responses that circulated through the lymphatics, blood, and lung. In contrast, antigen-LNPs alone stimulated weak and transient T cell responses. The enhanced T cell immunogenicity of Corner Therapeutics’ Catalytic Adjuvant platform was also observed for antibody production. The unique attributes of catalytic adjuvant vaccines may be particularly effective in vaccines designed to treat or prevent cancers and infectious diseases.

"This publication is an exciting milestone for Corner Therapeutics, offering the first overview of our catalytic adjuvants as tools to stimulate unprecedented vaccine immunogenicity," said Jonathan Kagan, Ph.D., Scientific Co-founder and Advisor at Corner Therapeutics and lead author of the publication. "The 2023 Nobel Prize in Physiology or Medicine was awarded to the researchers whose discoveries enabled the development of mRNA vaccines against COVID-19. This publication highlights Corner’s ambition to further advance this groundbreaking work, providing the first example of a simple and effective adjuvant for mRNA-LNP vaccines. We look forward to making continued breakthroughs in personalized and off-the-shelf vaccines through the development of our Catalytic Adjuvant platform."

"These data present a tremendous opportunity to partner with biopharma companies that share Corner’s commitment to bringing durable immunity to patients living with infectious diseases and cancer," said Steven Altschuler, M.D., CEO of Corner Therapeutics. "As we continue to develop our Catalytic Adjuvant platform, we look forward to exploring its broad potential to generate lifelong immunity for patients young and old."